Inicio/Acciones/GMAB

GMAB

USD

Genmab A/S ADS

$28.975+0.435 (1.524%)

Precio en Tiempo Real

Healthcare

Biotecnología

Dinamarca

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$28.540

Máximo

$29.390

Mínimo

$28.510

Volumen

2.92M

Fundamentos de la Empresa

Capitalización de Mercado

17.8B

Industria

Biotecnología

País

Denmark

Estadísticas de Negociación

Volumen Promedio

2.00M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $17.235Actual $28.975Máximo $33.65

Noticias Relacionadas

3 nov 2025 · 14:05

BusinessWire

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

15 oct 2025 · 10:29

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab with a Buy and maintains $40 price target.

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

14 oct 2025 · 10:23

GlobeNewswire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,